PLAY PODCASTS
S2 Ep21: OncView™ Podcast: EGFR Exon 20 Insertion as Therapeutic Target in NSCLC
Season 2 · Episode 21

S2 Ep21: OncView™ Podcast: EGFR Exon 20 Insertion as Therapeutic Target in NSCLC

Oncology On The Go

April 8, 202221m 1s

Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

As part of its OncView™ video series, CancerNetwork® spoke with Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a lung cancer medical oncologist at Massachusetts General Hospital, about recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions.

In the video series, Piotrowska discussed the following:

·      Overview of Advanced NSCLC with EGFR Mutations Including Exon 20 Insertions
·      Testing for the EGFR Exon 20 Insertion
·      Historical Treatment Approach for EGFR Exon 20 Insertions in NSCLC
·      Amivantamab for the Treatment of EGFR Exon 20 Insertions in NSCLC
·      Mobocertinib for the Treatment of EGFR Exon 20 Insertions in NSCLC
·      Treatment Selection for Patients With EGFR Exon 20 Insertions in NSCLC
·      Unmet Needs and Future Directions

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.